AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24724878 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education (WHE)
Number of subjects: 353
Study 22609980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryorecanalization procedure
Number of subjects: 40
Study 20306851 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Dermatophagoides pteronyssinus extract (SIT group, n = 89)
Number of subjects: 155
Study 20306851 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (control group, n = 66)
Number of subjects: 155
Study 20306851 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Dermatophagoides pteronyssinus extract (SIT group)
Number of subjects: 155
Study 20306851 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (control group)
Number of subjects: 155
Study 18546665 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level training group (learned based on spacing, or second-order relations, of the blobs)
Number of subjects: 0
Study 18546665 — intervention group
Group type: COMPARATOR
Intervention: Basic-level training group (learned based on the number of constituent blobs)
Number of subjects: 0
Study 15749459 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg amlodipine tablet formulation
Number of subjects: 36
Study 12739704 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (8 mg + 4 mg + 4 mg, administered 12 h and 2 h before, and 7 h after the start of the recording)
Number of subjects: 9
Study 12739704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12739704 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 9
Study 10394526 — intervention group
Group type: EXPERIMENTAL
Intervention: Falcon dishes
Number of subjects: 100
Study 10394526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nunc dishes
Number of subjects: 100
Study 8703558 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-0910 (10 mg or 20 mg daily)
Number of subjects: 12
Study 1992318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bjork-Shiley mechanical prosthesis
Number of subjects: 533
Study 1992318 — intervention group
Group type: COMPARATOR
Intervention: Porcine prosthesis
Number of subjects: 533
Study 6336984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (VDS)
Number of subjects: 47
Study 6336984 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and Cyclophosphamide (D/C)
Number of subjects: 47
Study 30729947 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine containing 2.5% chlorhexidine and 2.5% cetrimide (EXP)
Number of subjects: 15
Study 30729947 — intervention group
Group type: COMPARATOR
Intervention: Control group (CNT) with no antibacterial agents
Number of subjects: 15
Study 29130810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1.26% sodium bicarbonate
Number of subjects: 5177
Study 29130810 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 0.9% sodium chloride
Number of subjects: 5177
Study 29130810 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetylcysteine
Number of subjects: 5177
Study 29130810 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 5177
Study 27268282 — intervention group
Group type: EXPERIMENTAL
Intervention: Third intervention strategy (combined approach)
Number of subjects: 0
Study 27268282 — intervention group
Group type: COMPARATOR
Intervention: First intervention strategy (availability heuristic)
Number of subjects: 0
Study 27268282 — intervention group
Group type: COMPARATOR
Intervention: Second intervention strategy (affect heuristic)
Number of subjects: 0
Study 24444659 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiographic (TTE) imaging
Number of subjects: 40
Study 24444659 — intervention group
Group type: EXPERIMENTAL
Intervention: RV fractional area change < 25%
Number of subjects: 40
Study 24444659 — intervention group
Group type: EXPERIMENTAL
Intervention: RV end-diastolic area index of 18 cm²/m²
Number of subjects: 40
Study 22976492 — intervention group
Group type: EXPERIMENTAL
Intervention: ACH-1625 (monotherapy)
Number of subjects: 36
Study 20236198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pale sulfonated shale oil (PSSO) cream 4%
Number of subjects: 99
Study 20236198 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 99
Study 17662293 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of red wine (4.0+/‐0.4 dl)
Number of subjects: 22
Study 17662293 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of red wine (8.1+/‐0.9 dl)
Number of subjects: 22
Study 17662293 — intervention group
Group type: COMPARATOR
Intervention: De-alcoholized red wine
Number of subjects: 22
Study 17662293 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of red wine
Number of subjects: 22
Study 15933926 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 l polyethylene glycol (PEG)
Number of subjects: 231
Study 15933926 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 l PEG plus 10 mg Bisacodyl
Number of subjects: 231
Study 15933926 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 ml sodium phosphate
Number of subjects: 231
Study 12619669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of Japanese persimmon (kaki)
Number of subjects: 0
Study 12619669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of freeze-dried kaki
Number of subjects: 0
Study 12619669 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating a cookie with equivalent nutritional content to kaki
Number of subjects: 0
Study 12619669 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking finger in ice-cooled water after kaki consumption
Number of subjects: 0
Study 12619669 — intervention group
Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 0
Study 10554854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cross-clamp (Group I; n = 13)
Number of subjects: 38
Study 10554854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating-heart on pump without aortic cross-clamp (Group II; n = 12)
Number of subjects: 38
Study 10554854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating-heart without use of extracorporeal circulation (Group III; n = 13)
Number of subjects: 38
Study 8908380 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 treatment with regular insulin from day 8 to 12 and GLP-1 only at meals on days 13 and 14
Number of subjects: 12
Study 8908380 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 treatment
Number of subjects: 12
Study 8908380 — intervention group
Group type: COMPARATOR
Intervention: Control group (insulin only)
Number of subjects: 12
Study 1842206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hart modified Ritchie index
Number of subjects: 4
Study 1842206 — intervention group
Group type: EXPERIMENTAL
Intervention: American Rheumatism Association (ARA) index
Number of subjects: 4
Study 1842206 — intervention group
Group type: COMPARATOR
Intervention: Ritchie index
Number of subjects: 4
Study 1842206 — intervention group
Group type: COMPARATOR
Intervention: Simplified Lansbury index
Number of subjects: 4
Study 6419594 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg auranofin daily
Number of subjects: 2
Study 6419594 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg auranofin daily
Number of subjects: 2
Study 6419594 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg auranofin daily
Number of subjects: 2
Study 6419594 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg auranofin daily
Number of subjects: 2
Study 28912054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventions including patient, laboratory, and individualized CV risk assessments; treatment recommendations; prescription adaptations; and regular monthly follow-up for 3 months.
Number of subjects: 290
Study 28912054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventions
Number of subjects: 290
Study 26718805 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin (TI) during URTI
Number of subjects: 20
Study 26718805 — intervention group
Group type: EXPERIMENTAL
Intervention: Technosphere inhaled insulin (TI) during meal challenges
Number of subjects: 20
Study 25764287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ligation of the inferior mesenteric artery (IMA)
Number of subjects: 100
Study 25764287 — intervention group
Group type: COMPARATOR
Intervention: High ligation of the inferior mesenteric artery (IMA)
Number of subjects: 100
Study 23597262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive E-mail based intervention
Number of subjects: 1060
Study 23597262 — intervention group
Group type: COMPARATOR
Intervention: Brief advice on smoking cessation (Control)
Number of subjects: 1060
Study 20538951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 20538951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18537977 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HLA-DR15
Number of subjects: 103
Study 18537977 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PNH-type cells
Number of subjects: 103
Study 18537977 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anti-PMS1 antibody
Number of subjects: 103
Study 18537977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HLA-DR15, no PNH-type cells, no anti-PMS1 antibody)
Number of subjects: 103
Study 17767017 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte therapy (immunization by isolated lymphocytes from husbands, 50 to 100 million washed and resuspended mononuclear cells injected by I.V., S.C., and I.D. route, repeated immunization if needed)
Number of subjects: 92
Study 17767017 — intervention group
Group type: COMPARATOR
Intervention: Control group (81 age‐matched non‐pregnant RSA women, not immunized)
Number of subjects: 92
Study 17767017 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte therapy in primary aborters
Number of subjects: 92
Study 17767017 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte therapy in secondary aborters
Number of subjects: 92
Study 14631611 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-comparator trials
Number of subjects: 0
Study 14631611 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study 10894866 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose regimen (arm A): doxorubicin (50 mg/m² on day 1) and ifosfamide (5 g/m² on day 1)
Number of subjects: 314
Study 10894866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified regimen (arm B): doxorubicin (75 mg/m² on day 1), ifosfamide (5 g/m² on day 1), and rhGM-CSF (250 microgram/m² on days 3 to 16)
Number of subjects: 314
Study 8625677 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (70% helium:30% oxygen)
Number of subjects: 11
Study 1612959 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine (pH 7.3)
Number of subjects: 54
Study 1612959 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine (pH 6.5)
Number of subjects: 54
Study 6139040 — intervention group
Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine maleate sustained release tablets (6 mg b.d.)
Number of subjects: 61
Study 6139040 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide nasal spray (200 micrograms b.d.)
Number of subjects: 61
Study 30868672 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PDT (Aktilite®, 630 nm, 37 J/cm2, 8 min)
Number of subjects: 774
Study 30868672 — intervention group
Group type: COMPARATOR
Intervention: Half-time PDT (Aktilite®, 630 nm, 37 J/cm2, 4 min)
Number of subjects: 774
Study 30868672 — intervention group
Group type: COMPARATOR
Intervention: Half-time PDT
Number of subjects: 774
Study 30868672 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional PDT
Number of subjects: 774
Study 29787486 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning with random dot stimuli (RDS) in the form of a computer video game
Number of subjects: 32
Study 27777180 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily inhaled corticosteroids (ICSs)
Number of subjects: 300
Study 27777180 — intervention group
Group type: COMPARATOR
Intervention: Daily leukotriene receptor antagonists
Number of subjects: 300
Study 27777180 — intervention group
Group type: COMPARATOR
Intervention: As-needed ICS treatment coadministered with albuterol
Number of subjects: 300
Study 24667440 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab (INX)
Number of subjects: 429
Study 24667440 — intervention group
Group type: COMPARATOR
Intervention: etanercept
Number of subjects: 429
Study 24667440 — intervention group
Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 429
Study 22323300 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical face masks worn by patients with MDR-TB
Number of subjects: 17
Study 22323300 — intervention group
Group type: COMPARATOR
Intervention: No surgical face masks worn by patients with MDR-TB (control group)
Number of subjects: 17
Study 19021920 — intervention group
Group type: EXPERIMENTAL
Intervention: Organically produced carrots (200 g/d; 2 weeks)
Number of subjects: 36
Study 19021920 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally produced carrots (200 g/d; 2 weeks)
Number of subjects: 36
Study 19021920 — intervention group
Group type: COMPARATOR
Intervention: No carrots (control group)
Number of subjects: 36
Study 17583105 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine hydrochloride
Number of subjects: 20
Study 17583105 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 15140462 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation program
Number of subjects: 0
Study 11784874 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 154
Study 11784874 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin
Number of subjects: 154
Study 9817267 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (cumulative doses greater than 950 mg/m2)
Number of subjects: 469
Study 9817267 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 469
Study 9817267 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous irradiation against the heart
Number of subjects: 469
Study 8079617 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 82
Study 8079617 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 82
Study 2491827 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms
Number of subjects: 130
Study 2491827 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms
Number of subjects: 130
Study 2491827 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 130
Study 2491827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 984241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 66
Study 984241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31539053 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month controlled diet and supervised exercise program
Number of subjects: 14
Study 31539053 — intervention group
Group type: COMPARATOR
Intervention: Cycles with LPDs
Number of subjects: 14
Study 31539053 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in LH pulse frequency
Number of subjects: 14
Study 31118140 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib and GSK2141795
Number of subjects: 14
Study 28647012 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 28647012 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 36
Study 25955227 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment for 6 months
Number of subjects: 41
Study 23676807 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal haemorrhoidal dearterialisation with mucopexy (THD)
Number of subjects: 124
Study 23676807 — intervention group
Group type: COMPARATOR
Intervention: Stapler haemorrhoidopexy (SH)
Number of subjects: 124
Study 21828236 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant protein-D (SP-D) levels
Number of subjects: 1264
Study 21828236 — intervention group
Group type: EXPERIMENTAL
Intervention: Krebs von Lungren-6 (KL-6) levels
Number of subjects: 1264
Study 21828236 — intervention group
Group type: COMPARATOR
Intervention: SP-D levels among controls with CXR scarring
Number of subjects: 1264
Study 21828236 — intervention group
Group type: COMPARATOR
Intervention: KL-6 levels among controls with CXR scarring
Number of subjects: 1264
Study 19212272 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 19212272 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study 17685736 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75 mg/day to 300 mg/day)
Number of subjects: 258
Study 17685736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 14717655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (2.7 mmol/l)
Number of subjects: 15
Study 14717655 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemia (4.7 mmol/l)
Number of subjects: 15
Study 11591895 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily administration of gentamicin (6.5 mg/kg starting dose, adjusted to 7.3 mg/kg per day)
Number of subjects: 52
Study 11591895 — intervention group
Group type: COMPARATOR
Intervention: Multiple-daily administration of gentamicin (6.8 mg/kg per day)
Number of subjects: 52
Study 9711100 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test after myocardial infarction
Number of subjects: 0
Study 9711100 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative exercise test
Number of subjects: 0
Study 9711100 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive exercise test
Number of subjects: 0
Study 9711100 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine postinfarction exercise test
Number of subjects: 0
Study 7992810 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of Tc-99m pertechnetate at acupuncture point K-3 (Taixi)
Number of subjects: 157
Study 7992810 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of Tc-99m pertechnetate at other acupuncture points (APs)
Number of subjects: 157
Study 7992810 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of Tc-99m pertechnetate at non-acupuncture points (NAPs)
Number of subjects: 157
Study 2659954 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 (new steroid drug taken orally)
Number of subjects: 0
Study 2659954 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 0
Study 2659954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30924265 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) for 12 weeks, three times a week.
Number of subjects: 66
Study 30924265 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (control group).
Number of subjects: 66
Study 28497899 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 263
Study 28497899 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAO devices
Number of subjects: 263
Study 26202811 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase plus oral fingolimod 0.5 mg daily for 3 consecutive days
Number of subjects: 25
Study 26202811 — intervention group
Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 25
Study 22841937 — intervention group
Group type: EXPERIMENTAL
Intervention: RapidArc (Volumetric-modulated arc therapy)
Number of subjects: 20
Study 22841937 — intervention group
Group type: COMPARATOR
Intervention: Fixed-field IMRT (Intensity-modulated radiotherapy)
Number of subjects: 20
Study 22028623 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with gemcitabine and bevacizumab
Number of subjects: 20
Study 19455550 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery (ROB)
Number of subjects: 65
Study 19455550 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (LAP)
Number of subjects: 65
Study 19455550 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy (LSC)
Number of subjects: 65
Study 16445555 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 171
Study 16445555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 171
Study 16445555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CM and CBT
Number of subjects: 171
Study 14519887 — intervention group
Group type: COMPARATOR
Intervention: CarboStent (C; n = 168)
Number of subjects: 329
Study 14519887 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless-steel stent (S; n = 161)
Number of subjects: 329
Study 12382151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 2.0 g/kg given over 24 or 48 hours
Number of subjects: 22
Study 12382151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12382151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 22
Study 9651568 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (3 X 250 mg daily for 12 weeks)
Number of subjects: 18
Study 9651568 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (3 X 250 mg daily for 12 weeks) in a subgroup of 8 patients with baseline TG > 4 mmol L-1
Number of subjects: 18
Study 7543955 — intervention group
Group type: EXPERIMENTAL
Intervention: rG.CSF (5 micrograms/kg/d, d.i.v.)
Number of subjects: 95
Study 7543955 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated group)
Number of subjects: 95
Study 2539830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (CLO) supplementation (25 ml daily for 8 weeks)
Number of subjects: 40
Study 368817 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of chlorpromazine
Number of subjects: 10
Study 368817 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of amitriptyline
Number of subjects: 10
Study 368817 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 10
Study 368817 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg of dextroamphetamine sulfate
Number of subjects: 10